SIGA Technologies Appoints New CEO and CMO
Ticker: SIGA · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1010086
| Field | Detail |
|---|---|
| Company | Siga Technologies Inc (SIGA) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, leadership-change, personnel
TL;DR
SIGA names Dr. Dennis H. Smith permanent CEO, effective Oct 1st. New CMO also appointed.
AI Summary
SIGA Technologies, Inc. announced on October 4, 2024, that its Board of Directors appointed Dr. Dennis H. Smith as Chief Executive Officer, effective October 1, 2024. Dr. Smith, who has been serving as interim CEO since July 2024, will also join the Board of Directors. The company also announced the appointment of Dr. Michael J. Y. Lee as Chief Medical Officer.
Why It Matters
The appointment of a permanent CEO and a CMO signifies a new leadership direction for SIGA Technologies, potentially impacting its strategic focus and operational execution in the pharmaceutical sector.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and does not involve significant financial transactions or operational changes that would inherently increase risk.
Key Players & Entities
- SIGA Technologies, Inc. (company) — Registrant
- Dr. Dennis H. Smith (person) — Appointed CEO and Board Member
- Dr. Michael J. Y. Lee (person) — Appointed CMO
- October 4, 2024 (date) — Filing Date
- October 1, 2024 (date) — Effective Date of CEO Appointment
- July 2024 (date) — Start of Interim CEO Role
FAQ
Who has been appointed as the new Chief Executive Officer of SIGA Technologies, Inc.?
Dr. Dennis H. Smith has been appointed as the new Chief Executive Officer of SIGA Technologies, Inc.
When did the appointment of Dr. Dennis H. Smith as CEO become effective?
The appointment of Dr. Dennis H. Smith as CEO became effective on October 1, 2024.
What other significant executive appointment was announced by SIGA Technologies?
SIGA Technologies also announced the appointment of Dr. Michael J. Y. Lee as Chief Medical Officer.
What role did Dr. Dennis H. Smith hold prior to his permanent CEO appointment?
Prior to his permanent CEO appointment, Dr. Dennis H. Smith was serving as the interim CEO since July 2024.
Will the new CEO also join the Board of Directors?
Yes, Dr. Dennis H. Smith will also join the Board of Directors.
Filing Stats: 813 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-10-04 16:07:04
Filing Documents
- ef20036718_8k.htm (8-K) — 30KB
- ef20036718_ex10-1.htm (EX-10.1) — 29KB
- ef20036718_ex10-2.htm (EX-10.2) — 24KB
- 0001140361-24-042883.txt ( ) — 226KB
- siga-20241001.xsd (EX-101.SCH) — 4KB
- siga-20241001_lab.xml (EX-101.LAB) — 21KB
- siga-20241001_pre.xml (EX-101.PRE) — 16KB
- ef20036718_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2024, SIGA Technologies, Inc. (the "Company") entered into (i) an amendment to the employment agreement with Daniel J. Luckshire, the Company's Chief Financial Officer (the "Luckshire Amendment") and (ii) an amendment to the employment agreement with Dr. Dennis E. Hruby, the Company's Chief Scientific Officer (the "Hruby Amendment"). The Luckshire Amendment and the Hruby Amendment adjust the mix of Mr. Luckshire and Dr. Hruby's incentive compensation opportunities to increase the use of long-term incentives and thereby further align their interests with the long-term interests of the Company and its stockholders. Pursuant to the Luckshire Amendment and the Hruby Amendment, Mr. Luckshire and Dr. Hruby will each be eligible to: (i) earn a target annual bonus equal to (A) with respect to 2025, 75% of the executive's annual base salary and (B) with respect to 2026 and each calendar year thereafter, 50% of the executive's annual base salary and (ii) receive grants of equity awards with a target aggregate grant date value equal to (A) in 2025, 50% of the executive's annual base salary, (B) in 2026, 75% of the executive's annual base salary and (C) in 2027 and each calendar year thereafter, 100% of the executive's annual base salary. In addition, the Luckshire Amendment adjusts certain of Mr. Luckshire's severance entitlements to align with the severance entitlements of other similarly situated executive officers of the Company. Specifically, the Luckshire Amendment provides that if Mr. Luckshire experiences a qualifying termination of employment during the period that begins 90 days prior to the occurrence of a change of control of the Company and ends on the second anniversary of the occurrence of a change of control, then Mr. Luckshire will be entitled to, subject to his execution of a release of
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) The following exhibits are included in this report: Exhibit No. Description 10.1 Amendment to Amended and Restated Employment Agreement between SIGA Technologies, Inc. and Daniel J. Luckshire, dated as of October 1, 2024. 10.2 Second Amendment to Third Amended and Restated Employment Agreement between SIGA Technologies, Inc. and Dennis E. Hruby, dated as of October 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGA TECHNOLOGIES, INC. By: /s/ Daniel J. Luckshire Name: Daniel J. Luckshire Title: Chief Financial Officer Date: October 4, 2024